Track topics on Twitter Track topics that are important to you
Teva Pharmaceutical Industries Ltd 's earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning. But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform rating on Teva with an unchanged $39 price target.
Original Article: Teva's Quarter: Earnings Miss, Guidance Cut, Dividend DevastatedNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...